<DOC>
	<DOCNO>NCT01103583</DOCNO>
	<brief_summary>The pathogenesis MS remain elusive , however study link disease infection Epstein-Barr virus ; therefore use drug immunosuppressive immunomodulating action alone may less suitable primary progressive MS.This study evaluate treatment hydroxyurea ( HU ) primary progressive MS. Hydroxyurea act inhibit synthesis deoxynucleotides essential viral transcription , HU recently use combination antiretroviral drug HIV show limit immune activation suppress viral load antiviral cytostatic activity . Furthermore demonstrate experimentally HU suppress expression EBV . For reason HU could useful primary progressive MS cytostatic antiviral action , confirm role EBV pathogenesis MS .</brief_summary>
	<brief_title>Hydroxyurea Primary Progressive Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<criteria>sign write informed consent 18 60 year age inclusive diagnosis PPMS accord McDonald criterion EDSS score screen 27 inclusive hypersensitivity hydroxyurea patient treat immunosuppressive drug steroid three month respiratory urinary infection history presence malignancy pregnancy lactation low compliance therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>